Cargando…
Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
INTRODUCTION: Endothelial dysfunction is a risk factor for cardiovascular disease in patients with diabetes. We hypothesized that imeglimin, a novel oral hypoglycemic agent, would improve endothelial function. METHODS: In this study, imeglimin was administered to patients with type 2 diabetes and Hb...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981829/ https://www.ncbi.nlm.nih.gov/pubmed/36732433 http://dx.doi.org/10.1007/s13300-023-01370-z |
_version_ | 1784900193160790016 |
---|---|
author | Uchida, Taisuke Ueno, Hiroaki Konagata, Ayaka Taniguchi, Norifumi Kogo, Fumiko Nagatomo, Yuma Shimizu, Koichiro Yamaguchi, Hideki Shimoda, Kazuya |
author_facet | Uchida, Taisuke Ueno, Hiroaki Konagata, Ayaka Taniguchi, Norifumi Kogo, Fumiko Nagatomo, Yuma Shimizu, Koichiro Yamaguchi, Hideki Shimoda, Kazuya |
author_sort | Uchida, Taisuke |
collection | PubMed |
description | INTRODUCTION: Endothelial dysfunction is a risk factor for cardiovascular disease in patients with diabetes. We hypothesized that imeglimin, a novel oral hypoglycemic agent, would improve endothelial function. METHODS: In this study, imeglimin was administered to patients with type 2 diabetes and HbA1c ≥ 6.5% who were not receiving insulin therapy. A meal tolerance test (592 kcal, glucose 75.0 g, fat 28.5 g) was performed before and 3 months after administration, and endothelial function, blood glucose, insulin, glucagon, and triglycerides were evaluated. Endothelial function was assessed by flow-mediated dilation (FMD). RESULTS: Twelve patients (50% male) with a median age of 55.5 years old (interquartile range [IQR] 51.3–66.0) were enrolled. Fasting FMD did not differ before or 3 months after imeglimin administration (from 6.1 [3.9–8.5] to 6.6 [3.9–9.0], p = 0.092), but 2 h postprandial FMD was significantly improved 3 months after imeglimin administration (from 2.3 [1.9–3.4] to 2.9 [2.4–4.7], p = 0.013). In terms of the glucose profile, imeglimin administration significantly improved HbA1c (from 7.2 ± 0.6% to 6.9 ± 0.6%, p = 0.007), fasting glucose (from 138 ± 19 mg/dL to 128 ± 20 mg/dL, p = 0.020), and 2 h postprandial glucose (from 251 ± 47 mg/dL to 215 ± 68 mg/dL, p = 0.035). The change in 2 h postprandial FMD between before and 3 months after imeglimin administration (Δ2 h postprandial FMD) was negatively correlated with Δ2 h postprandial glucose (r = − 0.653, p = 0.021) in a univariate correlation coefficient analysis. Both patients with and without decreased postprandial glucose 3 months after imeglimin administration had improved postprandial FMD. CONCLUSION: In this small study, imeglimin administration improved 2 h postprandial FMD. Both glycemic control-dependent and -independent mechanisms might contribute to improved endothelial function. TRIAL REGISTRATION: This research was registered in the University Hospital Medical Information Network (UMIN, UMIN000046311). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01370-z. |
format | Online Article Text |
id | pubmed-9981829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-99818292023-03-04 Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study Uchida, Taisuke Ueno, Hiroaki Konagata, Ayaka Taniguchi, Norifumi Kogo, Fumiko Nagatomo, Yuma Shimizu, Koichiro Yamaguchi, Hideki Shimoda, Kazuya Diabetes Ther Original Research INTRODUCTION: Endothelial dysfunction is a risk factor for cardiovascular disease in patients with diabetes. We hypothesized that imeglimin, a novel oral hypoglycemic agent, would improve endothelial function. METHODS: In this study, imeglimin was administered to patients with type 2 diabetes and HbA1c ≥ 6.5% who were not receiving insulin therapy. A meal tolerance test (592 kcal, glucose 75.0 g, fat 28.5 g) was performed before and 3 months after administration, and endothelial function, blood glucose, insulin, glucagon, and triglycerides were evaluated. Endothelial function was assessed by flow-mediated dilation (FMD). RESULTS: Twelve patients (50% male) with a median age of 55.5 years old (interquartile range [IQR] 51.3–66.0) were enrolled. Fasting FMD did not differ before or 3 months after imeglimin administration (from 6.1 [3.9–8.5] to 6.6 [3.9–9.0], p = 0.092), but 2 h postprandial FMD was significantly improved 3 months after imeglimin administration (from 2.3 [1.9–3.4] to 2.9 [2.4–4.7], p = 0.013). In terms of the glucose profile, imeglimin administration significantly improved HbA1c (from 7.2 ± 0.6% to 6.9 ± 0.6%, p = 0.007), fasting glucose (from 138 ± 19 mg/dL to 128 ± 20 mg/dL, p = 0.020), and 2 h postprandial glucose (from 251 ± 47 mg/dL to 215 ± 68 mg/dL, p = 0.035). The change in 2 h postprandial FMD between before and 3 months after imeglimin administration (Δ2 h postprandial FMD) was negatively correlated with Δ2 h postprandial glucose (r = − 0.653, p = 0.021) in a univariate correlation coefficient analysis. Both patients with and without decreased postprandial glucose 3 months after imeglimin administration had improved postprandial FMD. CONCLUSION: In this small study, imeglimin administration improved 2 h postprandial FMD. Both glycemic control-dependent and -independent mechanisms might contribute to improved endothelial function. TRIAL REGISTRATION: This research was registered in the University Hospital Medical Information Network (UMIN, UMIN000046311). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01370-z. Springer Healthcare 2023-02-03 2023-03 /pmc/articles/PMC9981829/ /pubmed/36732433 http://dx.doi.org/10.1007/s13300-023-01370-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Uchida, Taisuke Ueno, Hiroaki Konagata, Ayaka Taniguchi, Norifumi Kogo, Fumiko Nagatomo, Yuma Shimizu, Koichiro Yamaguchi, Hideki Shimoda, Kazuya Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study |
title | Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study |
title_full | Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study |
title_fullStr | Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study |
title_full_unstemmed | Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study |
title_short | Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study |
title_sort | improving the effects of imeglimin on endothelial function: a prospective, single-center, observational study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981829/ https://www.ncbi.nlm.nih.gov/pubmed/36732433 http://dx.doi.org/10.1007/s13300-023-01370-z |
work_keys_str_mv | AT uchidataisuke improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy AT uenohiroaki improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy AT konagataayaka improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy AT taniguchinorifumi improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy AT kogofumiko improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy AT nagatomoyuma improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy AT shimizukoichiro improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy AT yamaguchihideki improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy AT shimodakazuya improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy |